COVID-19 vaccination program in the Philippines
CNCAV: Immunization with AstraZeneca vaccine - recommended for 18 to 55 age group
Immunization against COVID-19 with AstraZeneca vaccine is recommended for the 18 to 55 age group, with the possibility of increasing this range as new scientific data emerge, and the recommended time interval between the two doses is 8 weeks, the National COVID-19 Vaccination Coordination Committee (CNCAV) specified on Thursday.
The main topic of the world media is Serbian success with vaccination process
The main topic of the show is the success that Serbia has achieved in terms of procurement of vaccines and immunization of the population.
Brnabic pointed out at the start of the interview that Serbia was involved in the process of procuring vaccines from the very beginning.
Foto: Printskrin
Turkey passes 2-million mark in COVID-19 vaccinations
The number of people who have received the first dose of the COVID-19 vaccine has crossed the 2-million mark in Turkey.
The country, with a population of 83 million, rolled out its inoculation program on Jan. 17. Mostly health care professionals and the elderly have been administered the jab which Turkey secured from the Chinese firm Sinovac.
Orban was waiting to see how the vaccination would go in Serbia
He added that the country was waiting to see how the mass vaccination with the Chinese vaccine in Serbia would go.
In early January, Serbia received one million doses of the Chinese vaccine Sinopharm, and thus became the first European country to start a mass vaccination program with that vaccine, Reuters reports.
Number of people vaccinated for COVID exceeds 1.5 mln in Turkey
The number of people in Turkey who have received their first dose of a vaccine against the novel coronavirus crossed the 1.5 million mark as of Janç 27, according to official figures.
In week two of Turkey's mass vaccination campaign, in which it is administering CoronaVac jabs purchased from Chinese company SinoVac, immunization efforts are running smoothly, officials say.